Prevalence and Correlates of Positive Follow-up Screens in Primary Care for Unhealthy Alcohol and Other Drug Use After a Negative Screen.

Autor:	Alford DP; From the Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA (DPA, TWK, JHS, ABC, CWS, RS); Department of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA (JHS, RS); Institute for Behavioral Health, Heller School for Social Policy and Management, Brandeis University, Waltham, MA, USA (MFB)., Kim TW, Samet JH, Cruz AB, Brolin MF, Shanahan CW, Saitz R
Jazyk:	angličtina
Zdroj:	Journal of addiction medicine [J Addict Med] 2022 Jul-Aug 01; Vol. 16 (4), pp. e219-e224. Date of Electronic Publication: 2021 Nov 18.
DOI:	10.1097/ADM.0000000000000917
Abstrakt:	Objective: To determine the proportion and characteristics of adults in primary care (PC) who screen positive for unhealthy substance use (SU) (alcohol and/or other drug) 1 year or more after screening negative. Methods: Screening consisted of single-item questions for unhealthy use of alcohol and other drugs (illicit drugs and prescription medications). Health educators conducted in-person screening of patients presenting for a PC appointment. SU severity (low, moderate, high) was assessed with the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). Multivariate logistic regression models estimated predictors of a positive follow-up screen. Results: Among 9215 patients who previously screened negative, 237 (2.6%) screened positive for unhealthy SU (42% alcohol only, 43% other drug only, 15% alcohol and other drug). The mean interval between screens was 19 months. Most alcohol use was low risk (ASSIST score ≤10) (81%), whereas most drug use was moderate risk (ASSIST score 4-26) (77%). Patients between ages of 18 to 25 had a higher proportion of positive follow-up screens (7.4% [33/ 443]) as well as those with a self-identified history of SU problems (9.4% [40/421]). Patients with a higher odds of a positive follow-up screen were male (adjusted odds ratio [AOR] 2.64; 95% CI: 2.02-3.45), used tobacco (AOR 2.38; 95% CI: 1.75-3.23), had a longer interval between screenings (AOR 3.26; 95% CI: 1.84-5.75). Conclusions: Screening for unhealthy SU 1 year or more after screening negative identified additional patients at-risk. These findings highlight the need to empirically determine the incremental benefits of screening all PC patients annually. Competing Interests: The authors report that Richard Saitz is the Principal Investigator of an NIH/NIAAA-supported (to Boston University [BU]) study of people with alcohol use disorder; BU receives injectable naltrexone for that study from Alkermes. The remaining authors report no conflicts of interest. (Copyright © 2021 American Society of Addiction Medicine.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu